FGF2 and myeloproliferative disorder: Decreased malignant megakaryocytes led to reduced growth factors (e.g., platelet-derived growth factor (PDGF), fibroblast growth factor 2 (FGF-2)) and inflammatory cytokines, hence reduction in BM fibrosis in MPN cultures [242] A pilot study suggested that additional spliceosome mutations (e.g., U2AF1, SF3B1) might lead to suboptimal telomerase upregulation and increase patients’ sensitivity to telomerase inhibition [244] (Table 3).